|Bid||37.39 x 100|
|Ask||44.98 x 300|
|Day's Range||39.41 - 40.31|
|52 Week Range||19.21 - 50.90|
|PE Ratio (TTM)||30.79|
|Forward Dividend & Yield||0.80 (2.00%)|
|1y Target Est||N/A|
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
PetMed (PETS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.
The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.
Assessing PetMed Express Inc’s (NASDAQ:PETS) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, whichRead More...
Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.
Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.
Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.
Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base
Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.